Skip to content

Psilocybin: all studies

Page 350 of 441: studies 3,491 to 3,500 of 4,401, newest first. Back to the psilocybin overview

Research

Integrating the ineffable: a social phenomenological analysis of the psychedelic experience

Library, Museums and Press - UDSpace (University of Delaware) February 4, 2025 Logan Neitzke-Spruill 2 citations

"There has been a renewed and growing interest in psychedelic drugs in the 21st century. Drawing on social-phenomenology, cognitive sociology, and ‘set and setting’ theory, I delineate how individuals use socially defined frameworks of understanding to attribute meaning to psychedelic experiences. These frameworks refer to the ‘ready-made’ schemes that structure subjective experience of...

DOI: 10.58088/dyjg-0344 (opens in new tab) Interpretative phenomenological analysis Epistemology

Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent.

Psychopharmacology Bulletin February 3, 2025 Anna Mori-Kreiner, Arpit Aggarwal, Meelie Bordoloi 8 citations

Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual symptoms that an individual experienced while intoxicated with a hallucinogenic substance when the individual is sober. While there are several case reports of HPPD in adult patients, there is a scarcity of documented cases in children and adolescents. The...

DOI: 10.1016/j.biopha.2021.112295 (opens in new tab) Full text (opens in new tab) Hallucinogen-persisting perception disorder Hallucinogenic use Mental illness Polysubstance use +3

BEHAVIORAL ANALYSES OF ANTIDEPRESSANT-LIKE EFFECT OF SEROTONERGIC PSYCHEDELICS IN MICE

The International Journal of Neuropsychopharmacology February 1, 2025 *Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.

Abstract Background Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through the serotonin 5-HT2A receptor (5-HT2A). Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. Aims & Objectives The involvement of...

DETERMINATION OF TRYPTAMINE ALKALOIDS AND THEIR STABILITY IN PSYCHOTROPIC MUSHROOMS

The International Journal of Neuropsychopharmacology February 1, 2025 Martin Kuchař, Klara Gotwaldova, Jan Borovička et al. 1 citation

Abstract Synthetic psilocybin (PSB), but also the PSB-containing mushrooms are used for psychedelic therapy and microdosing. It is necessary to know alkaloids variability and stability in wild-grown mushrooms. Concentrations of other psychotropic (or potentially psychotropic) tryptamines such as psilocin (PS), baeocystin (BA), norbaeocystin (NB), and aeruginascin (AE) are also relevant. This...

Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.

Current Psychiatry Reports February 1, 2025 Jamarie Geller, Eric Whitney 3 citations

There is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability. The aim of this review is to report on outcomes of clinical trials for psilocybin-assisted psychotherapy for adults with depression and MDMA-assisted psychotherapy for adults with post-traumatic stress disorder (PTSD) and discuss recommendations for...

Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review.

Journal of Psychosomatic Research February 1, 2025 Ana Esteves Ferreira, Paulo Reis-Pina 3 citations

Psychedelic-Assisted Therapy (PAT) is gaining traction as a novel approach to addressing the psychological and existential distress experienced by patients. This systematic review aimed to investigate the impact of PAT on spirituality, mystical experiences, and spiritual well-being (SpWB) in patients with life-threatening, incurable, or terminal illnesses. A comprehensive search was conducted...

The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour

International Journal of Mental Health Nursing February 1, 2025 Eva Louie, Ellen Towers, Alyssa R Morse et al. 2 citations

ABSTRACT Australian government approval has been granted for 3,4‐methylenedioxy‐methamphetamine (MDMA) treatment of post‐traumatic stress disorder and psilocybin for treatment‐resistant depression, but the process of translating psychedelic‐assisted therapies (PAT) into more widespread use is complex. Along with establishing the efficacy and feasibility of PATs, their acceptability amongst...

DOI: 10.1111/inm.70010 (opens in new tab) Psychedelic therapy Acceptability Mental health consumer Psychedelic‐assisted therapy +4

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 31, 2025 Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano et al. 27 citations

Neuroinflammation is a critical factor in the pathogenesis of various neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and major depressive disorder. Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), have demonstrated promising therapeutic effects on neuroinflammation, primarily through interactions...

Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects

Journal of Psychoactive Drugs January 29, 2025 Carrie Cuttler, Amanda Stueber, Jonathan J. Simone et al. 3 citations

The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better understand the nature of psychedelic use by the general population. To this end, 1,486 eligible respondents (Mage = 29.58, 67.1% male) residing in the United States completed an online survey designed to assess the types of psychedelics used, methods of...

DOI: 10.1080/02791072.2025.2452226 (opens in new tab) Acute effects Administration methods Intentions Psychedelics +4

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).

Scientific Reports January 29, 2025 Richard J. Zeifman, Meg J. Spriggs, Hannes Kettner et al. 26 citations

The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs. We conducted a preliminary examination of two psychological assumptions of REBUS: (a) psychedelics foster acute relaxation and post-acute revision of confidence in mental-health-relevant beliefs; which (b) facilitate positive...

DOI: 10.1038/s41598-023-28111-3 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Cognitive flexibility Psychedelics Mental health